



**Proposed ASX code: PIQ**

Box 3008, Broadway, Nedlands  
Perth WA 6009  
Australia

ABN 78 169 979 971  
Telephone: +61 8 9389 1992  
Facsimile: +61 8 6151 1038  
Email: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

## **PROTEOMICS INTERNATIONAL LABORATORIES LAUNCHES \$6m IPO**

**Established revenue generating life sciences company focused in the area of proteomics**

### **Highlights**

- **Offer of up to 30m shares at 20c to raise \$6m (\$4m minimum subscription).**
- **Offer scheduled to close November 28 with expected ASX listing December 16, 2014.**
- **Company specialises in the area of proteomics – the study of the structure and function of proteins.**
- **Operates in three synergistic business units each in massive growth markets - Analytical services, Diagnostics and Therapeutics.**
- **Proceeds of IPO will be used to expand and grow each business unit.**
- **Substantial portfolio of clients and partners and a global standing its field.**
- **High calibre board and management with specific expertise in science technology, business operations and business growth.**

Emerging life science company Proteomics International Laboratories Ltd (proposed ASX: PIQ) is pleased to announce that it has launched its prospectus for a new IPO to raise up to \$6 million via the issue of 30 million shares at 20c each.

The minimum subscription amount is \$4 million.

PIQ is a specialist technology-driven life sciences company founded in 2001 and based in Perth, Australia. It is an established, revenue generating business with a focus on the area of proteomics, and has generated gross income of \$7.5 million to date.

The Company's business model is based on its proprietary technology platform which operates across three synergistic business units in massive growth markets;

- 1. Analytical services** - Specialist contract research, analytical testing and consultancy - fee for service model. Proteomics market estimated to be worth \$20.8b by 2018.
- 2. Diagnostics** - Biomarkers of disease and personalised medicine - focus on diabetic kidney disease and Alzheimer's disease. Biomarkers market estimated to be worth \$40.8b by 2018.

**3. Therapeutics** - Peptide drug discovery from venoms with a focus on painkillers and antibiotics. Peptide therapeutics market currently estimated to be worth \$17b.

The synergy arises from PIQ's technology platform, which can be applied to each unit simultaneously. The output from each can feed development and growth in the others. This maximises the opportunity for the Company to use its resources to generate revenue and create new intellectual property - which in turn can be sold, licensed, or retained to generate further revenues.

The proceeds of the IPO will be used to expand and accelerate the growth of each business unit.

The Company has a substantial portfolio of clients and partners, including; CSIRO, Reliance Life Sciences, inVentive Health Clinical, Australian National University, National University of Singapore and University of Western Australia.

PIQ has a global standing its field. Its laboratory was the first facility in the world to receive ISO 17025 laboratory accreditation for proteomics services, and its team of 20 operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth.

The Offer opened November 3, and is scheduled to close November 28, with an anticipated ASX listing date of December 16, 2014.

PIQ has a highly credentialed board, which includes; Managing Director and co-founder Dr Richard Lipscombe, a highly experienced and successful business manager and protein chemist; Chairman Terry Sweet, a scientific-technology company director and executive with 30 years experience (see Board profiles attached).

The Financial Adviser and Lead Manager to the Offer is Sydney-based corporate advisory firm K S Capital.

### **What is proteomics**

Proteomics is the study of the structure and function of proteins. The protein make-up in our bodies differs from cell to cell and changes considerably over time. For example, a cancerous cell will have significantly different proteins to a healthy cell. Understanding proteomics can speed up diagnosis and the identification of drugs that can be used to treat diseases.

As recently as 12-15 years ago, identifying a single protein (a process called sequencing) took 24 hours, and required comparatively large amounts of highly purified sample. Today, PIQ can identify a protein in 10 seconds and complex mixtures can be quickly and accurately analysed. This drives the Company's business model across its three areas of operation.

ENDS

#### **For further information please contact;**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [r.lipscombe@proteomicsinternational.com](mailto:r.lipscombe@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Mr Greg Wood  
Managing Director  
K S Capital  
T: +61 416 076 377  
E: [g.wood@kscapital.com.au](mailto:g.wood@kscapital.com.au)

#### Media and Investor Inquiries

James Moses  
Mandate Corporate  
T: +61 420 991 574  
E: [james@mandatecorporate.com.au](mailto:james@mandatecorporate.com.au)

## **THE BOARD**

### **Mr Terry Sweet FAICD – Non-Executive Chairman**

Director of a number of listed companies over the past 30 years in both executive and non-executive capacities, including; XRF Scientific Ltd, where he was Managing Director for four years, Western Biotechnology Ltd, Heartlink Ltd, and Scientific Services Ltd. Mr Sweet is a chemist by training.

### **Dr Richard Lipscombe PhD (London), MA (Oxford) – Managing Director**

Co-founder of the Company. He is a highly successful business manager and protein chemist and is expert in analysing bio-molecules using proteomics techniques. He has international experience in science and business gained over a 29-year period. Dr Lipscombe has a chemistry degree (MA) from Oxford University, a PhD in immunology from London University and was a Post-Doctoral scientist (molecular immunology) at a large Australian research institution. After managing the Protein Analysis Facility at the University of Western Australia, he co-founded PIQ in 2001.

### **Mr John Dunlop BSc – Non-Executive Director**

Has been a director of a number of ASX-Listed companies in the areas of mineral exploration, finance and analytical laboratories. Was a founding director of beta-carotene producer, Western Biotechnology Ltd (subsequently acquired by Hoffman-La-Roche) and founding director of Sheen Analytical Services.

### **Dr Bill Parker PhD (UWA), BSc (London) - Non-Executive Director**

Fellow co-founder of the Company with Dr Lipscombe. Has more than 30 years experience in university and commercial laboratories, including establishing and managing a NATA-accredited analytical laboratory. Has a PhD in microbiology and was a founding director of ASX-listed Western Biotechnology Ltd. Has been a consultant to the WA State government in technology development, and technology park management. He was also a director of the Australian Solar Council.